top of page

Ochre Bio CEO Jack O'Meara discusses his company's focus on liver diseases and its recent Boehringer Ingelheim partnership

  • blonca9
  • May 6, 2024
  • 1 min read

Jack O'Meara describes Ochre's unique preclinical testing strategy as it develops siRNA drugs for liver diseases, and he touches on a high profile partnership the company signed in recent weeks.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

bottom of page